Should I buy or sell Twist Bioscience stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Twist Bioscience in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TWST shares. View TWST analyst ratings or view top-rated stocks .

What is Twist Bioscience's stock price target for 2024?

4 equities research analysts have issued twelve-month price targets for Twist Bioscience's shares. Their TWST share price targets range from $27.00 to $45.00. On average, they predict the company's share price to reach $36.40 in the next year. This suggests a possible upside of 28.3% from the stock's current price. View analysts price targets for TWST or view top-rated stocks among Wall Street analysts .

How have TWST shares performed in 2024?

Twist Bioscience's stock was trading at $36.86 at the beginning of 2024. Since then, TWST stock has decreased by 23.1% and is now trading at $28.36. View the best growth stocks for 2024 here .

When is Twist Bioscience's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our TWST earnings forecast .

How were Twist Bioscience's earnings last quarter?

Twist Bioscience Co. (NASDAQ:TWST) released its earnings results on Friday, February, 2nd. The company reported ($0.75) earnings per share for the quarter, beating analysts' consensus estimates of ($0.78) by $0.03. The business earned $71.50 million during the quarter, compared to the consensus estimate of $67.59 million. Twist Bioscience had a negative trailing twelve-month return on equity of 32.16% and a negative net margin of 78.44%. The company's quarterly revenue was up 31.8% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.74) earnings per share.

What ETFs hold Twist Bioscience's stock?

ETFs with the largest weight of Twist Bioscience (NASDAQ:TWST) stock in their portfolio include ARK Genomic Revolution ETF (ARKG) , Subversive Mental Health ETF (SANE) , iShares Genomics Immunology and Healthcare ETF (IDNA) , WisdomTree BioRevolution Fund (WDNA) , Global X Telemedicine & Digital Health ETF (EDOC) , BNY Mellon Innovators ETF (BKIV) , ROBO Global Healthcare Technology and Innovation ETF (HTEC) and ARK Innovation ETF (ARKK) .

What guidance has Twist Bioscience issued on next quarter's earnings?

Twist Bioscience updated its second quarter 2024 earnings guidance on Friday, February, 2nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $70.0 million-$71.0 million, compared to the consensus revenue estimate of $70.1 million.

What is Emily Leproust's approval rating as Twist Bioscience's CEO?

44 employees have rated Twist Bioscience Chief Executive Officer Emily Leproust on Glassdoor.com . Emily Leproust has an approval rating of 83% among the company's employees.

What other stocks do shareholders of Twist Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Twist Bioscience investors own include CrowdStrike (CRWD) , Pfizer (PFE) , DocuSign (DOCU) , Intel (INTC) , NVIDIA (NVDA) , Advanced Micro Devices (AMD) , Gilead Sciences (GILD) , JD.com (JD) , Tesla (TSLA) and Twilio (TWLO) .

When did Twist Bioscience IPO?

Twist Bioscience (TWST) raised $75 million in an initial public offering (IPO) on Wednesday, October 31st 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan and Cowen acted as the underwriters for the IPO and Allen & Company and Baird were co-managers.

Who are Twist Bioscience's major shareholders?

Twist Bioscience's stock is owned by many different institutional and retail investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (6.14%) and Green Alpha Advisors LLC (0.03%). Insiders that own company stock include Adam Laponis, Dennis Cho, Emily M Leproust, Emily M Leproust , James M Thorburn , Jan Johannessen , John P Molloy, Keith Crandell , Nicolas Barthelemy, Patrick John Finn , Patrick Weiss , Paula Green , Robert Chess , Robert F Werner and William Banyai . View institutional ownership trends .

How do I buy shares of Twist Bioscience?

Shares of TWST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:TWST

Twist Bioscience (TWST) Stock Price, News & Analysis

→ Don’t expose yourself to stocks during the week (From DTI) (Ad)

Free TWST Stock Alerts

$28.19

-0.17 (-0.60%)

(As of 12:39 PM ET)

Compare

Today's Range: $28.15
▼
$29.20
50-Day Range: $28.36
▼
$41.50
52-Week Range: $11.46
▼
$43.21

Volume: 336,353 shs
Average Volume: 908,848 shs
Market Capitalization: $1.63 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $36.40

Get Twist Bioscience alerts:

Twist Bioscience MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 28.3% Upside
$36.40 Price Target
Short Interest: Bearish
21.20% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.42
Upright™ Environmental Score
News Sentiment: 0.56
Based on 8 Articles This Week
Insider Trading: Selling Shares
$384,092 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($3.17) to ($2.81) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.17 out of 5 stars

Medical Sector

294th out of 918 stocks

Biological Products, Except Diagnostic Industry

42nd out of 155 stocks

3.5

Analyst's Opinion

Consensus Rating
Twist Bioscience has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Twist Bioscience has only been the subject of 2 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
21.20% of the outstanding shares of Twist Bioscience have been sold short.
Short Interest Ratio / Days to Cover
Twist Bioscience has a short interest ratio ("days to cover") of 13.5, which indicates bearish sentiment.
Change versus previous month
Short interest in Twist Bioscience has recently increased by 2.08%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Twist Bioscience does not currently pay a dividend.
Dividend Growth
Twist Bioscience does not have a long track record of dividend growth.

4.4

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Twist Bioscience has received a 65.93% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Deoxyribonucleic acid (DNA)" and "Monoclonal antibodies for research" products. See details.
Environmental Sustainability
The Environmental Impact score for Twist Bioscience is -1.42.

2.0

News and Social Media Coverage

News Sentiment
Twist Bioscience has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 8 news articles for Twist Bioscience this week, compared to 3 articles on an average week.
Search Interest
Only 5 people have searched for TWST on MarketBeat in the last 30 days. This is a decrease of -38% compared to the previous 30 days.
MarketBeat Follows
Only 8 people have added Twist Bioscience to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Twist Bioscience insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $384,092.00 in company stock.
Percentage Held by Insiders
Only 3.92% of the stock of Twist Bioscience is held by insiders.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Twist Bioscience are expected to grow in the coming year, from ($3.17) to ($2.81) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Twist Bioscience is -7.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Twist Bioscience is -7.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Twist Bioscience has a P/B Ratio of 2.61. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Insiders Exposed

The Hard Truth About Investing For Retirement

Here’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.

Click To Access This Powerful Training Right Now!

About Twist Bioscience Stock (NASDAQ:TWST)

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

TWST Stock Price History

30 days | 90 days | 365 days | Advanced Chart

TWST Stock News Headlines

April 12, 2024 | insidertrades.com

Insider Selling: Twist Bioscience Co. (NASDAQ:TWST) CFO Sells 556 Shares of Stock

April 5, 2024 | insidertrades.com

Twist Bioscience Co. (NASDAQ:TWST) Insider William Banyai Sells 327 Shares

April 19, 2024 | Insiders Exposed (Ad)

The Hard Truth About Investing For Retirement

April 5, 2024 | insidertrades.com

Insider Selling: Twist Bioscience Co. (NASDAQ:TWST) COO Sells 492 Shares of Stock

March 23, 2024 | insidertrades.com

Twist Bioscience Co. (NASDAQ:TWST) CEO Sells $37,810.56 in Stock

April 18, 2024 | businesswire.com

Twist Bioscience to Report Fiscal 2024 Second Quarter Financial Results on Thursday, May 2, 2024

April 14, 2024 | investing.com

Cathie Wood’s ARK ETFs buy Roku, Twist Bioscience stock

April 13, 2024 | investing.com

Twist Bioscience CFO sells shares to cover taxes

April 19, 2024 | Insiders Exposed (Ad)

The Hard Truth About Investing For Retirement

April 13, 2024 | americanbankingnews.com

Adam Laponis Sells 556 Shares of Twist Bioscience Co. (NASDAQ:TWST) Stock

April 12, 2024 | morningstar.com

Twist Bioscience Corp TWST

April 12, 2024 | finance.yahoo.com

Twist Bioscience Corporation (TWST)

April 12, 2024 | americanbankingnews.com

Twist Bioscience (NASDAQ:TWST) Shares Gap Down on Analyst Downgrade

April 11, 2024 | americanbankingnews.com

Twist Bioscience (NASDAQ:TWST) PT Lowered to $40.00 at Barclays

April 10, 2024 | markets.businessinsider.com

Analyst Scoreboard: 5 Ratings For Twist Bioscience

April 6, 2024 | investing.com

Twist Bioscience exec sells shares to cover tax withholding

April 3, 2024 | markets.businessinsider.com

Analysts Are Bullish on These Healthcare Stocks: Atossa Therapeutics (ATOS), Arbutus Biopharma (ABUS)

March 28, 2024 | businesswire.com

Twist Bioscience Launches Pangenome Spike-in Exome Panel to Enable Advancement of Research for Diverse Populations

March 21, 2024 | markets.businessinsider.com

Buy Rating Justified: Twist Bioscience’s Strong Demand and Strategic Expansion Signal Market Share Growth

March 13, 2024 | finance.yahoo.com

Twist Bioscience Launches IVDR-compliant Precision Dx Products for Whole Exome Sequencing

March 7, 2024 | uk.investing.com

Twist Bioscience launches EU-compliant diagnostic products

March 2, 2024 | finance.yahoo.com

TWST Apr 2024 42.500 put

February 22, 2024 | finance.yahoo.com

Twist Bioscience to Present at Upcoming Investor Conferences

February 22, 2024 | businesswire.com

Twist Bioscience to Present at Upcoming Investor Conferences

February 17, 2024 | ca.finance.yahoo.com

TWST Jul 2024 42.500 call

February 17, 2024 | finance.yahoo.com

TWST Mar 2024 45.000 put

February 17, 2024 | finance.yahoo.com

TWST Mar 2024 25.000 call

See More Headlines

Receive TWST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Twist Bioscience and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/02/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/03/2024
Fiscal Year End: 9/30/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:TWST
CUSIP: N/A
CIK: 1581280
Web: www.twistbioscience.com
Phone: (800) 719-0671
Fax: N/A
Employees: 919
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $36.40
High Stock Price Target: $45.00
Low Stock Price Target: $27.00
Potential Upside/Downside: +28.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.61)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-204,620,000.00
Net Margins: -78.44%
Pretax Margin: -77.99%
Return on Equity: -32.16%
Return on Assets: -26.09%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.98
Quick Ratio: 5.51

Sales & Book Value

Annual Sales: $245.11 million
Price / Sales: 6.69
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $10.86 per share
Price / Book: 2.61

Miscellaneous

Outstanding Shares: 57,820,000
Free Float: 55,552,000
Market Cap: $1.64 billion
Optionable: Optionable
Beta: 1.62

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

Dr. Emily Marine Leproust Ph.D. (Age 50)
Co-Founder, Chairman & CEO
Comp: $1.37M
Dr. Patrick John Finn Ph.D. (Age 52)
President & COO
Comp: $943.94k
Ms. Paula Green (Age 56)
Senior Vice President of Human Resources
Comp: $618.48k
Dr. William Charles Banyai Ph.D. (Age 69)
Senior VP of Advanced Development, GM of Data Storage & Director
Comp: $711.34k
Mr. Adam Laponis (Age 47)
Chief Financial Officer
Mr. Robert F. Werner (Age 51)
VP & Chief Accounting Officer
Mr. Siyuan Chen
Chief Technology Officer
Dr. Aaron K. Sato Ph.D.
Chief Scientific Officer
Mr. Chet Gandhi
Chief Information Officer
Mr. Dennis Cho (Age 53)
Senior VP, Chief Legal Officer & Corporate Secretary
Comp: $537.93k

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

TWST Stock Analysis - Frequently Asked Questions

Should I buy or sell Twist Bioscience stock right now?: 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Twist Bioscience in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TWST shares.
View TWST analyst ratings or view top-rated stocks.
What is Twist Bioscience's stock price target for 2024?: 4 equities research analysts have issued twelve-month price targets for Twist Bioscience's shares. Their TWST share price targets range from $27.00 to $45.00. On average, they predict the company's share price to reach $36.40 in the next year. This suggests a possible upside of 28.3% from the stock's current price.
View analysts price targets for TWST or view top-rated stocks among Wall Street analysts.
How have TWST shares performed in 2024?: Twist Bioscience's stock was trading at $36.86 at the beginning of 2024. Since then, TWST stock has decreased by 23.1% and is now trading at $28.36.
View the best growth stocks for 2024 here.
When is Twist Bioscience's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our TWST earnings forecast.
How were Twist Bioscience's earnings last quarter?: Twist Bioscience Co. (NASDAQ:TWST) released its earnings results on Friday, February, 2nd. The company reported ($0.75) earnings per share for the quarter, beating analysts' consensus estimates of ($0.78) by $0.03. The business earned $71.50 million during the quarter, compared to the consensus estimate of $67.59 million. Twist Bioscience had a negative trailing twelve-month return on equity of 32.16% and a negative net margin of 78.44%. The company's quarterly revenue was up 31.8% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.74) earnings per share.
What ETFs hold Twist Bioscience's stock?: ETFs with the largest weight of Twist Bioscience (NASDAQ:TWST) stock in their portfolio include ARK Genomic Revolution ETF (ARKG), Subversive Mental Health ETF (SANE), iShares Genomics Immunology and Healthcare ETF (IDNA), WisdomTree BioRevolution Fund (WDNA), Global X Telemedicine & Digital Health ETF (EDOC), BNY Mellon Innovators ETF (BKIV), ROBO Global Healthcare Technology and Innovation ETF (HTEC) and ARK Innovation ETF (ARKK).

What guidance has Twist Bioscience issued on next quarter's earnings?: Twist Bioscience updated its second quarter 2024 earnings guidance on Friday, February, 2nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $70.0 million-$71.0 million, compared to the consensus revenue estimate of $70.1 million.
What is Emily Leproust's approval rating as Twist Bioscience's CEO?: 44 employees have rated Twist Bioscience Chief Executive Officer Emily Leproust on Glassdoor.com. Emily Leproust has an approval rating of 83% among the company's employees.
What other stocks do shareholders of Twist Bioscience own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Twist Bioscience investors own include CrowdStrike (CRWD), Pfizer (PFE), DocuSign (DOCU), Intel (INTC), NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), JD.com (JD), Tesla (TSLA) and Twilio (TWLO).
When did Twist Bioscience IPO?: Twist Bioscience (TWST) raised $75 million in an initial public offering (IPO) on Wednesday, October 31st 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan and Cowen acted as the underwriters for the IPO and Allen & Company and Baird were co-managers.
Who are Twist Bioscience's major shareholders?: Twist Bioscience's stock is owned by many different institutional and retail investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (6.14%) and Green Alpha Advisors LLC (0.03%). Insiders that own company stock include Adam Laponis, Dennis Cho, Emily M Leproust, Emily M Leproust, James M Thorburn, Jan Johannessen, John P Molloy, Keith Crandell, Nicolas Barthelemy, Patrick John Finn, Patrick Weiss, Paula Green, Robert Chess, Robert F Werner and William Banyai.
View institutional ownership trends.
How do I buy shares of Twist Bioscience?: Shares of TWST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TWST) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Twist Bioscience (TWST) Stock Price, News & Analysis

Twist Bioscience MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Twist Bioscience Stock (NASDAQ:TWST)

TWST Stock Price History

TWST Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

TWST Stock Analysis - Frequently Asked Questions

Overall MarketRank^™